Effect of Magnesium Supplementation in COPD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2019-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Magnesium (Mg) is involved in several pathways that could be affected in chronic obstructive pulmonary diseases (COPDs), namely in the contractility and excitability of neuro-muscolar endothelial cells and low-grade inflammation, a typical state of COPD. In this sense, several randomized controlled trials (RCTs) confirmed a positive role of Mg in asthma since long-period oral supplementation of Mg leads to a clinical and spirometric improvement.

Subjects with COPD seem to have a reduced bioavailability of Mg probably due to the use of drugs that may increase Mg losses (e.g. beta-agonists and cortisones), to a reduced dietary Mg intake, and heavy smoking. A recent study showed that the administration of endovenous or aerosol Mg sulphate with beta-agonists acutely improve maximum expiratory flow during COPD relapses as well as the prolonged treatment with endovenous sulphate Mg led to a reduction in pulmonary hyperinflation and increase in muscles involved in respiration, with a consequent clinical and instrumental improvement.

These evidences suggest that a chronic supplementation with Mg could improve COPD in clinical and instrumental parameters, but, at the best of our knowledge, no study was available in this sense.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Magnesium Loading in Chronic Obstructive Pulmonary Disease

NCT00500864

Chronic Obstructive Pulmonary Disease (COPD)

COMPLETED PHASE1/PHASE2

Effect of Magnesium Sulphate Infusion on Lung Mechanics and Oxygenation in COPD Patients Undergoing Total Laryngeal

NCT03461328

Chronic Obstructive Pulmonary Diseases

COMPLETED PHASE4

Involvement of Plasmatic Factors in the Peripheral Muscle Dysfunction of COPD Patients - In Vitro Study

NCT03197909

Chronic Obstructive Pulmonary

COMPLETED

AECOPD and Nutritional Supplementation in COPD

NCT06801964

Obstructive Pulmonary Disease Exacerbation Copd

COMPLETED NA

Nitrate Supplementation in Chronic Obstructive Pulmonary Disease (COPD)

NCT02084758

Chronic Obstructive Pulmonary Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Magnesium

300 mg of citrate Mg/daily

Group Type EXPERIMENTAL

300 mg of citrate Mg

Intervention Type DIETARY_SUPPLEMENT

This group will take an oral supplementation of 300 mg of citrate magnesium

Placebo

placebo group

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

This group will take a placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

300 mg of citrate Mg

This group will take an oral supplementation of 300 mg of citrate magnesium

Intervention Type DIETARY_SUPPLEMENT

Placebo

This group will take a placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (\>18 years).
* Moderate-severe COPD (FEV1 between 30-80% of theorical values).

Exclusion Criteria

* Already taking magnesium or calcium supplementations.
* Severe renal (creatinine clearance\< 30 ml/min) or hepatic decline or presence of other co-morbidities interfering with outcomes (e.g. dementia).
* Hypermagnesemia (serum Mg\>1.85 mmol/L).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No